Literature DB >> 17177208

Neuroprotection of retinal ganglion cells in DBA/2J mice with GDNF-loaded biodegradable microspheres.

M S Ward1, A Khoobehi, E B Lavik, R Langer, M J Young.   

Abstract

This study aims to promote long-term retinal ganglion cell (RGC) survival in a spontaneous glaucoma model by injecting slow-release Poly(DL-lactide-co-glycolide) (PLGA) microspheres containing glial cell line-derived neurotrophic factor (GDNF) into the vitreous. Microspheres (1 microL) suspended in PBS were injected in ipsilateral eyes while contralateral eyes served as untreated controls. Mice were injected at 2 months intervals (1-4 injections) depending on the protocol. ELISA assay indicated a cumulative GDNF release of 35.4 ng/mg over 71 days. The release was nonlinear with an initial burst of over 50%. Mice displayed a 30% drop in RGC density by 8 months (p = 0.013) and 80% drop by 10 months (p < 0.01). GDNF delivery increased RGC survival in all groups. Mice receiving early treatment showed up to 3.5 times greater RGC density than untreated mice at 15 months survival (p < 0.05). No significant effect was found in sham or lens injury groups. Microsphere-delivered GDNF significantly increases long-term RGC survival in a spontaneous glaucoma model, although the nonlinear release kinetics suggest that burst release may play a role in this rescue. Neuroprotection with slow-release polymers with improved release kinetics should be further studied as a potential therapy for glaucoma and other diseases involving the loss of central nervous system neurons. 2006 Wiley-Liss, Inc. and the American Pharmacists Association

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17177208     DOI: 10.1002/jps.20629

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  28 in total

1.  Transplantation of BDNF-secreting mesenchymal stem cells provides neuroprotection in chronically hypertensive rat eyes.

Authors:  Matthew M Harper; Sinisa D Grozdanic; Bas Blits; Markus H Kuehn; Daniel Zamzow; Janice E Buss; Randy H Kardon; Donald S Sakaguchi
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-06-23       Impact factor: 4.799

Review 2.  A perspective on the role of the extracellular matrix in progressive retinal degenerative disorders.

Authors:  Muayyad R Al-Ubaidi; Muna I Naash; Shannon M Conley
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-12-17       Impact factor: 4.799

3.  Nanospheres delivering the EGFR TKI AG1478 promote optic nerve regeneration: the role of size for intraocular drug delivery.

Authors:  Rebecca Robinson; Stephen R Viviano; Jason M Criscione; Cicely A Williams; Lin Jun; James C Tsai; Erin B Lavik
Journal:  ACS Nano       Date:  2011-06-09       Impact factor: 15.881

4.  Stem cell therapy for glaucoma: possibilities and practicalities.

Authors:  Thomas V Johnson; Natalie D Bull; Keith R Martin
Journal:  Expert Rev Ophthalmol       Date:  2011-04-01

5.  Neuroprotection of retinal ganglion cells with GDNF-Loaded biodegradable microspheres in experimental glaucoma.

Authors:  Jian-He Xiao; Mao-Nian Zhang
Journal:  Int J Ophthalmol       Date:  2010-09-18       Impact factor: 1.779

6.  A poly(ethylene) glycolylated peptide for ocular delivery compacts DNA into nanoparticles for gene delivery to post-mitotic tissues in vivo.

Authors:  Sarah Parker Read; Siobhan M Cashman; Rajendra Kumar-Singh
Journal:  J Gene Med       Date:  2010-01       Impact factor: 4.565

7.  Using polymer chemistry to modulate the delivery of neurotrophic factors from degradable microspheres: delivery of BDNF.

Authors:  James P Bertram; Millicent F Rauch; Kaliq Chang; Erin B Lavik
Journal:  Pharm Res       Date:  2009-11-17       Impact factor: 4.200

8.  Longitudinal evaluation of retinal ganglion cell function and IOP in the DBA/2J mouse model of glaucoma.

Authors:  Maher Saleh; Mahesh Nagaraju; Vittorio Porciatti
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-10       Impact factor: 4.799

Review 9.  Rodent models of glaucoma.

Authors:  Thomas V Johnson; Stanislav I Tomarev
Journal:  Brain Res Bull       Date:  2009-04-18       Impact factor: 4.077

10.  Ex vivo gene therapy using intravitreal injection of GDNF-secreting mouse embryonic stem cells in a rat model of retinal degeneration.

Authors:  Kevin Gregory-Evans; Francis Chang; Matthew D Hodges; Cheryl Y Gregory-Evans
Journal:  Mol Vis       Date:  2009-05-13       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.